Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Everest Forms Renal Research Partnership with Guangdong Medical Academy

publication date: Mar 24, 2023

Everest Medicines, a Shanghai biopharma, signed an MOU with the Guangdong Academy of Medical Sciences to partner renal disease research and translational studies. Everest develops innovative medicines and vaccines with an interest in kidney disease. Professor Xueqing Yu, a renowned nephrologist and President of the Academy, will lead the research. Everest's novel renal drugs include Nefecon, a first-in-disease therapy for primary immunoglobulin A nephropathy (IgAN) (currently under NDA review in China), and a BTK inhibitor in clinical trials for glomerular diseases. More details....

Stock Symbol: (HK: 1952)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital